Gelonghui, May 15 | Jinkai Biotech (301509.SZ) said on the investor interactive platform that the company is a small molecule CDMO service provider for global life science customers, providing customized R&D and production services for small molecule drug intermediates and small quantities of APIs for the new drug R&D projects of original pharmaceutical companies around the world. The company is an intermediate supplier for simeglutide oral penetration enhancer SNAC. The company has always insisted on deepening technology, continuously consolidating its main business, and striving to promote the company's high-quality and sustainable development.
金凯生科(301509.SZ)：是司美格鲁肽口服渗透促进剂SNAC的中间体供应商
Jinkai Shengke (301509.SZ): An intermediate supplier for the simeglutide oral penetration enhancer SNAC
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.